@article {jacquot_multi-institutional_nodate,
	title = {Multi-Institutional Experience with COVID-19 Convalescent Plasma in Children},
	journal = {Transfusion},
	volume = {n/a},
	number = {n/a},
	year = {2023},
	note = {_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.17318},
	abstract = {Background and Objectives Convalescent COVID-19 plasma (CCP) was developed and used worldwide as a treatment option by supplying passive immunity. Adult studies suggest administering high-titer CCP early in the disease course of patients who are expected to be antibody-negative; however, pediatric experience is limited. We created a multi-institutional registry to characterize pediatric patients (\&lt;18 years) who received CCP and assess the safety of this intervention. Methods A REDCap survey was distributed. The registry collected de-identified data including demographic information (age, gender, and underlying conditions), COVID-19 disease features and concurrent treatments, CCP transfusion and safety events, and therapy response. Results Ninety-five children received CCP: 90 inpatients and 5 outpatients, with a median age of 10.2 years (range 0-17.9), predominantly Latino/Hispanic and White. The most frequent underlying medical conditions were chronic respiratory disease, immunosuppression, obesity, and genetic syndromes. CCP was primarily given as a treatment (95\%) rather than prophylaxis (5\%). Median total plasma dose administered and transfusion rates were 5.0 mL/kg and 2.6 mL/kg/hr, respectively. The transfusions were well tolerated, with 3 in 115 transfusions reporting mild reactions. No serious adverse events were reported. Severity scores decreased significantly 7 days after CCP transfusion or at discharge. Eight-five patients (94.4\%) survived to hospital discharge. All five outpatients survived to 60 days. Conclusions CCP was found to be safe and well tolerated in children. CCP was frequently given concurrently with other COVID-19-directed treatments with improvement in clinical severity scores >= 7 days after CCP, but efficacy could not be evaluated in this study.},
	keywords = {COVID-19 convalescent plasma, pediatric transfusion, transfusion safety},
	issn = {1537-2995},
	doi = {10.1111/trf.17318},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1111/trf.17318},
	author = {Jacquot, Cyril and Gordon, Oren and Noland, Daniel and Donowitz, Jeffrey R. and Levy, Emily and Jain, Sanjay and Willis, Zachary and Rimland, Casey and Loi, Michele and Arrieta, Antonio and Annen, Kyle and Drapeau, Noelle and Osborne, Stephanie and Ardura, Monica I. and Arora, Satyam and Zivick, Elise and Delaney, Meghan}
}
